HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.

Abstract
Despite the known benefits and the experienced use of lopinavir/ritonavir (LPV/r) in the management of HIV infection, important interindividual variability in the pharmacokinetics (PKs) and the response to treatment with standard doses of this drug has been observed. Host genetic factors have been recently suggested as being responsible for part of this variability as they may affect the expression and functional activity of many proteins involved in the kinetic behavior, the immune recovery or the adverse effects related to LPV/r. Here, we present a genetic association study in 106 HIV-infected individuals collected over a period of 5 years with the aim of identifying and confirming single nucleotide polymorphisms (SNPs) with a significant influence on the PK parameters of LPV/r, the immunovirological response or toxicity derived from treatment with the studied drug. Genotyping was performed by MALDI-TOF and KASPar; LPV/r plasma concentrations were quantified using high-performance liquid chromatography with an ultraviolet detection system and the PK parameters were estimated using Bayesian algorithms. Genetic association analysis was performed with SPSS. The most significant associations were found between SNPs in the dopamine receptor D3 gene and the PK of LPV/r. Additionally, other suggestive relationships were established between genetic factors and the response during treatment with this drug. Thereby, identifying HIV-infected individuals who are at increased risk of achieve non-optimal LPV/r plasma concentrations with the emergence of toxicity, drug resistance or absence of clinical response could be helpful as a tool to optimize the LPV/r-based antiretroviral therapy.
AuthorsE López Aspiroz, S E Cabrera Figueroa, G L Porras Hurtado, R Cruz Guerrero, A Domínguez-Gil Hurlé, A Carracedo,
JournalCurrent drug metabolism (Curr Drug Metab) Vol. 14 Issue 7 Pg. 729-37 (Sep 2013) ISSN: 1875-5453 [Electronic] Netherlands
PMID24001122 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • DRD3 protein, human
  • HIV Protease Inhibitors
  • Lipids
  • Receptors, Dopamine D3
  • Lopinavir
  • Ritonavir
Topics
  • Adolescent
  • Adult
  • Aged
  • CD4 Lymphocyte Count
  • Drug Therapy, Combination
  • Female
  • Genotype
  • HIV Infections (blood, drug therapy, genetics, immunology)
  • HIV Protease Inhibitors (administration & dosage, blood, pharmacokinetics)
  • Humans
  • Lipids (blood)
  • Lopinavir (administration & dosage, blood, pharmacokinetics)
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Receptors, Dopamine D3 (genetics)
  • Ritonavir (administration & dosage, blood, pharmacokinetics)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: